Onyx Biotec Ltd

Onyx Biotec Annual General Meeting

Onyx Biotec Limited will hold its 21st Annual General Meeting on September 28, 2026, via video conferencing to transact the company's business.

Onyx Biotec Management Change

Onyx Biotec Limited has announced a change in the designation of Mr. Naresh Kumar from Whole-Time Director to Executive Director, effective September 3, 2026.

Onyx Biotec Board Meeting Outcome

Onyx Biotec Ltd. announced its board meeting outcomes, including the 21st AGM convening, cost auditor appointment, and a director's designation change to Managing Director.

Onyx Biotec Open Offer: ₹17.21 Cr

VC Corporate Advisors has filed a Detailed Public Statement for an open offer to acquire 26% stake in Onyx Biotec Limited at ₹36.50 per share.

Value

₹17.21 Cr

Onyx Biotec Other Announcement

Onyx Biotec Ltd states corporate‑governance rules do not apply as it is listed on NSE EMERGE and meets small‑cap criteria. The filing complies with SEBI Regulation 15.

Onyx Biotec Promoter Selling: ₹3.41 Cr

Promoters Sanjay Jain and Fateh Pal Singh disposed of equity shares. Sanjay Jain sold shares valued at ₹3.41 Crore via the open market.

Value

₹3.41 Cr

Onyx Biotec Promoter Selling

Promoter Fateh Pal Singh disclosed the sale of 124,000 (0.68%) equity shares of Onyx Biotec Ltd on the NSE. The disposal is recorded under SEBI Regulation 7.

Onyx Biotec Price Movement Clarification

Onyx Biotec clarified that recent share price volatility is purely market-driven with no undisclosed material information. The company reiterated its commitment to SEBI listing compliance.

Onyx Biotec Promoter Selling: ₹5.44 Cr

Promoter Sanjay Jain sold 17,74,000 shares of Onyx Biotec Limited for ₹5.44 Crore via the open market. This transaction reduced his equity stake from 21.48% to 11.70%.

Value

₹5.44 Cr

Onyx Biotec Management Change

Managing Director Sanjay Jain and Whole Time Director Lakshya Jain resigned from Onyx Biotec Ltd. Their departures are effective May 27, 2026, citing personal reasons.

Onyx Biotec Fund Raise of ₹25.38 Cr

Onyx Biotec Limited confirmed zero deviation in utilizing ₹25.38 Crore raised through its IPO. Funds were deployed for manufacturing upgrades, loan repayments, and general corporate purposes.

Value

₹25.38 Cr

Onyx Biotec H2 FY26 Results: Net Profit ₹0.7 Cr, Down 65.0% YoY

Onyx Biotec Ltd reported revenue from operations of ₹34.9 Cr (+9.7% YoY) and net profit of ₹0.7 Cr (-65.0% YoY) for H2 FY26.

Key figure

Net profit ₹0.7 Cr · -65.0% YoY

Onyx Biotec Financial Results

Onyx Biotec Limited approved audited financial results for the year ended March 31, 2026. The company reported utilization of ₹25.38 Crore from its recent IPO proceeds.

Value

₹25.38 Cr

Onyx Biotec Other Announcement

Onyx Biotec Limited submitted its annual compliance certificate for the Structured Digital Database for FY2026. The auditor confirmed full compliance with SEBI insider trading regulations.

Onyx Biotec Board Meeting Date

Onyx Biotec Limited has scheduled a Board Meeting for May 14, 2026, to consider and approve audited standalone financial results for the year ended March 31, 2026. The company's trading window remains closed until May 16, 2026.

Onyx Biotec Fund Raise of ₹25.38 Cr

Onyx Biotec Limited submitted an auditor-signed certificate confirming the utilization of Rs. 25.38 Crore in IPO proceeds for the half-year ended September 30, 2025. The funds were utilized for manufacturing unit upgradation, loan repayment, and general corporate purposes, with no reported deviations from the stated objects.

Value

₹25.38 Cr

Onyx Biotec Other Announcement

Onyx Biotec Limited's promoters have submitted their annual disclosure under SEBI (SAST) Regulations for the financial year ended March 31, 2026. The promoters declared that no direct or indirect encumbrances were created on the company's shares during this period. This confirms stable promoter shareholding with zero pledged shares for the year.